Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Breast 3Thoracic 1Plasma cell 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 3

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Docosahexaenoic Acids × Dermatologic × 1 year × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00087776 2025-07-23

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

American Regent, Inc.

Phase 3 Terminated
393 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡